Gene therapy could free gaucher patients from lifelong infusions

NCT ID NCT07223944

First seen Nov 03, 2025 · Last updated May 06, 2026 · Updated 24 times

Summary

This study tests a one-time gene therapy called FLT201 for adults with Gaucher disease type 1. Participants currently on regular enzyme replacement therapy will stop that treatment after receiving FLT201. The goal is to see if the gene therapy can keep blood counts stable and control the disease without ongoing medication. About 45 people will take part in this Phase 3 trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GAUCHER DISEASE, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Duke University Medical Center

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Lysosomal Rare Disorders Research and Treatment Center

    RECRUITING

    Fairfax, Virginia, 22030-6066, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Texas Southwestern

    RECRUITING

    Dallas, Texas, 75390, United States

Conditions

Explore the condition pages connected to this study.